Ritter Anett, Voedisch Bernd, Wienberg Johannes, Wilms Burkhard, Geisse Sabine, Jostock Thomas, Laux Holger
Novartis Institutes for BioMedical Research, Basel, Switzerland.
Novartis Pharma AG, Integrated Biologics Profiling Unit, Werk Klybeck Postfach CH-4002, Basel, Switzerland.
Biotechnol Bioeng. 2016 May;113(5):1084-93. doi: 10.1002/bit.25876. Epub 2015 Nov 20.
Chinese Hamster Ovary (CHO) cells are widely used for large scale production of recombinant biopharmaceuticals. Although these cells have been extensively used, a demand to further increase the performance, for example, to facilitate the process of clone selection to isolate the highest producing cell lines that maintain stability of production over time is still existing. We compared gene expression profiles of high versus low producing CHO clones to identify regulated genes which can be used as biomarkers during clone selection or for cell line engineering. We present evidence that increased production rates and cell line stability are correlated with the loss of the telomeric region of the chromosome 8. A new parental CHO cell line lacking this region was generated and its capability for protein production was assessed. The average volumetric productivity of cells after gene transfer and selection was found to be several fold improved, facilitating the supply of early drug substance material to determine for example, quality. In addition, significantly more cell clones with a higher average productivity and higher protein production stability were obtained with the new host cell line after single cell cloning. This allows reduced efforts in single cell sorting, screening of fewer clones and raises the opportunity to circumvent time and labor-intensive stability studies.
中国仓鼠卵巢(CHO)细胞被广泛用于大规模生产重组生物药物。尽管这些细胞已被广泛使用,但仍存在进一步提高其性能的需求,例如,便于进行克隆选择过程,以分离出随着时间推移保持生产稳定性的高产细胞系。我们比较了高产与低产CHO克隆的基因表达谱,以鉴定可在克隆选择期间用作生物标志物或用于细胞系工程的调控基因。我们提供的证据表明,生产率的提高和细胞系稳定性与8号染色体端粒区域的缺失相关。我们生成了一个缺少该区域的新的亲本CHO细胞系,并评估了其蛋白质生产能力。发现基因转移和选择后细胞的平均体积生产率提高了几倍,便于提供早期药物物质以确定例如质量。此外,使用新的宿主细胞系进行单细胞克隆后,获得了更多平均生产率更高且蛋白质生产稳定性更高的细胞克隆。这减少了单细胞分选的工作量,减少了克隆筛选数量,并增加了规避耗时且费力的稳定性研究的机会。